Home › Research › Biomarkers
Multimorbidity and fluid biomarkers of Alzheimer's disease: a systematic review
Valletta M, Canevelli M, Gasparini F, Buscarnera S, Salzillo M, Triolo F, Calderón-Larrañaga A, Marengoni A et al.. European geriatric medicine, 2025-05-20
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Purpose This systematic review aimed to summarize the evidence on the association between multimorbidity and fluid biomarkers of Alzheimer's disease (AD). Methods We systematically searched PubMed, Web of Science, and Embase for studies investigating the association between multimorbidity-defined as the co-occurrence of multiple chronic conditions in the same individual-and levels of cerebrospinal fluid (CSF) or blood biomarkers of AD, focusing on the most established AD biomarkers (amyloid-beta, phosphorylated-tau, total-tau, neurofilament light chain, and glial fibrillary acidic protein). Studies were selected following PRISMA guidelines. Results Out of 3,104 records, we identified 10 cross-sectional studies. Four studies assessed CSF biomarkers in dementia-free participants with mean age between 61.8 and 66.6 years, yielding mixed findings with no consistent association between multimorbidity and CSF biomarkers. Six studies focused on blood biomarkers in participants with mean age ranging from 66.5 to 76.4 years, five of which included individuals with dementia. Most of these studies reported an association between multimorbidity and elevated blood biomarker levels. Conclusions This review suggests a significant association between multimorbidity and AD blood biomarkers in older populations, while the results on CSF are mixed and inconsistent. Further research is needed, particularly longitudinal studies assessing both CSF and blood biomarkers within the same populations.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Valletta, M., Canevelli, M., Gasparini, F., Buscarnera, S., Salzillo, M., Triolo, F., et al. (2025). Multimorbidity and fluid biomarkers of Alzheimer's disease: a systematic review. European geriatric medicine. https://doi.org/10.1007/s41999-025-01222-y
Vancouver
Valletta M, Canevelli M, Gasparini F, Buscarnera S, Salzillo M, Triolo F, et al. Multimorbidity and fluid biomarkers of Alzheimer's disease: a systematic review. European geriatric medicine. 2025. doi:10.1007/s41999-025-01222-y. PMID: 40392441.
BibTeX
@article{valletta2025-40392441,
author = {Valletta, M. and Canevelli, M. and Gasparini, F. and Buscarnera, S. and Salzillo, M. and Triolo, F. and Calderón-Larrañaga, A. and Marengoni, A. and others},
title = {{Multimorbidity and fluid biomarkers of Alzheimer's disease: a systematic review}},
journal = {European geriatric medicine},
year = {2025},
doi = {10.1007/s41999-025-01222-y},
pmid = {40392441},
url = {https://doi.org/10.1007/s41999-025-01222-y}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results Out of 3,104 records, we identified 10 cross-sectional studies.
- Conclusions This review suggests a significant association between multimorbidity and AD blood biomarkers in older populations, while the results on CSF are mixed and inconsistent.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designsystematic review
- Evidence strengthHigh
How this study scored 72/100
Published in a peer-reviewed journal, and it is a systematic review of all the studies on the question. Scored zero for sample size, effect reported and studied in people because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 42 of the 58 points we could judge it on, which is 72 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (European geriatric medicine) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 12 / 12 | A systematic review of all the studies on the question |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | A review of other studies — randomization is not credited here |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40392441) |
| Free to read | 2 / 2 | Free to read |
| Points | 42 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 42 of the 58 points we could judge it on is 72 out of 100. |
| Total | 72 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.